Research & IP Evaluation Expertise

Our pharmaceutical intellectual property practice provides analysis, assessment and strategic advice on life science IP. The practice is focused on both helping clients extract maximum value from their IP portfolios and supporting companies and investors conducting IP due diligence.

The service is designed to sit alongside what is offered by established patent firms. We do not file and maintain patents, but provide high-level strategic advice. For example, patent applications and procedures can take on a life of their own, with organizational inertia masking the need for a decision. We can provide a realistic, commercially relevant reality check, helping clients rationalize and prioritize IP assets.

We also undertake intellectual property due diligence on behalf of an investor or acquirer to support a transaction or asset valuation.

Our technical areas of expertise span pharmaceutical chemistry, pharmacology, microbiology, biotechnology, genetic engineering, stem cells, physiology, pharmacogenomics, proteomics, plant and animal protection, medtech and medical instruments.


Featured Case Study: University intellectual property portfolio triage

Working with King’s College London, Alacrita helped to evaluate and prioritize life science research projects for funding and commercial support with the objective to help promising intellectual property attract and secure investor and partner interest. This assignment was conducted over several months and was composed of three phases:

1.  IP Audit

Using a project characterisation template running on a secure web-based platform, we surveyed several hundred PIs to identify potentially commercialisable projects with filed or patentable intellectual property. This encompassed the entire life science research portfolio of the university including therapeutics, biomarkers/diagnostics and medical devices.

2.  Project Prioritization

Our consulting team, comprised of pharmaceutical, biotech, diagnostics and medtech industry specialists, analysed the information received from the PIs and validated it through a combination of internal analysis, external research and telephone interviews with PIs. Projects were scored according to their:

  • Value in use
  • Market attractiveness
  • Developability

This allowed projects to be ranked into priority categories for the next stage of the analysis.

3. Techno-Commercial Development Plans

Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected projects which would benefit most from focussed financial support for work to reach one or more value-creating milestones and thereby progress toward partnering and/or spin-out goals.

Further case studies regarding Research and IP evaluation are available here.